EN CN

Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Blood Diseases Volume" for the treatment of Chinese patent medicines for blood diseases

2018-11-22





PREVShengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Tumor Disease Volume" anti-tumor Chinese patent medicine NEXTShengbai Oral Liquid: Progress and Prospect of Integrated Traditional Chinese and Western Medicine in Clinical Oncology

Hot news

How much do you know about leukopen...

Meta-analysis of the efficacy of S...

Efficacy of Shengbai mixture on bo...

A complete TCM treatment for leu...

Should leukopenia be discontinued i...

Polysaccharides were included in th...

Should I stop chemotherapy if I h...

What kind of treatment is needed fo...

Service hotline

0724-8886111

Address：3 Fuyao Yi Lu, Doudao District, Jingmen City, Hubei Province, China
Transmissionh：0724-8686500
Email：hbmy_monyan@163.com

COPYRIGHT© 2022 Hubei Mengyang Pharmaceutical Co., LTD. All Rights Reserved E ICP 11014915; Internet Drug Information Service Certificate No. : (E) - Non-business -2016-0032

Technical Support: SUMA